Opthea Limited (OPT) Bundle
An Overview of Opthea Limited (OPT)
General Summary of Opthea Limited (OPT)
Opthea Limited (OPT) is a clinical-stage biopharmaceutical company focused on developing novel therapies for eye diseases. Headquartered in Melbourne, Australia, the company specializes in developing treatments for retinal disorders.
| Company Detail | Specific Information |
|---|---|
| Founded | 2007 |
| Headquarters | Melbourne, Australia |
| Stock Exchange Listing | ASX, NASDAQ |
Key product focus includes OPT-302, a novel VEGF inhibitor targeting treatment of wet age-related macular degeneration (wet AMD).
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Cash Position | $133.5 million |
| Research & Development Expenses | $47.3 million |
| Net Loss | $48.9 million |
Industry Leadership
Opthea Limited is recognized for its innovative approach in ophthalmology therapeutic development, particularly in retinal disease treatments.
- Advancing Phase 3 clinical trials for OPT-302
- Targeting significant unmet medical needs in ophthalmology
- Developing precision therapies for retinal disorders
Mission Statement of Opthea Limited (OPT)
Mission Statement of Opthea Limited (OPT)
Opthea Limited (OPT) mission statement focuses on advancing ophthalmic therapeutics with innovative treatment solutions for retinal diseases.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Therapeutic Innovation | Developing advanced treatments for retinal disorders | OPT-302 clinical trial Phase 3 progression |
| Patient Outcomes | Improving visual function and quality of life | Targeting wet age-related macular degeneration (wAMD) market |
| Research Commitment | Investing in ophthalmology research | $35.4 million R&D expenditure in 2023 |
Strategic Research Objectives
- Develop novel therapies targeting retinal diseases
- Enhance treatment efficacy for wAMD patients
- Expand global therapeutic reach
Research Investment Metrics
| Year | R&D Investment | Clinical Trial Stage |
|---|---|---|
| 2022 | $29.6 million | Phase 2/3 trials |
| 2023 | $35.4 million | Phase 3 trials |
Market Opportunity
Global wet AMD market projected to reach $12.3 billion by 2027, with Opthea positioning OPT-302 as potential breakthrough therapy.
Key Performance Indicators
- Clinical trial success rate: 78%
- Patent portfolio: 15 granted patents
- Global research collaborations: 4 active partnerships
Vision Statement of Opthea Limited (OPT)
Vision Statement of Opthea Limited (OPT)
Innovative Ophthalmology Research FocusOpthea Limited aims to advance novel therapies for retinal diseases, specifically targeting wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Key Research Pipeline Metrics| Program | Current Stage | Development Status |
|---|---|---|
| OPT-302 | Phase 3 Clinical Trials | Ongoing Development |
| Complement Pathway Targeting | Advanced Research | Active Investigation |
- Develop innovative biologic therapies for retinal vascular diseases
- Pursue global regulatory approvals for OPT-302
- Maximize therapeutic potential in ophthalmology treatment landscape
As of 2024, Opthea has invested $48.3 million in research and development, with ongoing Phase 3 clinical trials for OPT-302 targeting wet AMD and DME markets.
Market Opportunity Assessment| Market Segment | Projected Value | Growth Potential |
|---|---|---|
| Wet AMD Treatment Market | $10.2 billion | 7.5% CAGR |
| Diabetic Macular Edema Market | $6.7 billion | 6.3% CAGR |
Core Values of Opthea Limited (OPT)
Core Values of Opthea Limited (OPT) in 2024
Scientific Innovation and Research ExcellenceOpthea Limited demonstrates commitment to scientific innovation through targeted research in ophthalmology, specifically focusing on novel treatments for retinal diseases.
| Research Investment | 2024 Metrics |
|---|---|
| R&D Expenditure | $23.4 million |
| Clinical Trial Stages | Phase 2b/3 for OPT-302 |
Opthea prioritizes patient outcomes through advanced therapeutic development targeting significant unmet medical needs in retinal diseases.
- Focused on wet age-related macular degeneration (wAMD) treatment
- Developing combination therapies to improve patient outcomes
- Targeting potential market of approximately 196,000 new wAMD cases annually
| Governance Metric | 2024 Status |
|---|---|
| Independent Board Members | 67% |
| Shareholder Communications | Quarterly financial reports |
Opthea maintains strategic partnerships to advance ophthalmological research and treatment development.
- Collaboration with Novartis for clinical development
- International research network engagement
Commitment to responsible business operations and sustainable pharmaceutical development.
| Sustainability Metric | 2024 Performance |
|---|---|
| Carbon Footprint Reduction | 15% reduction from 2023 baseline |
| Ethical Research Compliance | 100% adherence to international standards |
Opthea Limited (OPT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.